Home > Press > Sigma-Aldrich Enters Distribution Agreement With AlphaGenix, Inc.: Sigma-Aldrich to Carry Key Products for Regenerative Medicine and Stem Cell Biology
Sigma-Aldrich (Nasdaq: SIAL) today announced a distribution agreement with AlphaGenix, Inc., a leading developer and manufacturer of products for basic and clinical life science research. Sigma-Aldrich will now be the exclusive supplier of AlphaGenix-developed antibodies and research tools for the fields of regenerative medicine and stem cell biology. This partnership will further augment Sigma-Aldrich's growing product portfolio of life science tools for stem cell research (www.sigma-aldrich.com/stemcell).
Sigma-Aldrich Enters Distribution Agreement With AlphaGenix, Inc.: Sigma-Aldrich to Carry Key Products for Regenerative Medicine and Stem Cell Biology
ST. LOUIS, MO | Posted on November 13th, 2008
The new product offerings include antibodies to stem cell markers; tools for 3-D stem cell culture systems, such as MaxGel(TM), a human derived extracellular Matrix (ECM) and its components; and HydroMatrix(TM), a synthetic peptide scaffold that offers the precision and control of a synthesized matrix with the natural 3-D architecture of a highly crosslinked peptide hydrogel.
Over the past decade, researchers have developed a number of enhanced 3-D cell culture systems that better resemble in vivo systems. Both MaxGel and HydroMatrix promote cell growth and migration and have been shown to support the proliferation and enhance function of many cell types, including neural stem cells, neurons, glia, astrocytes, fibroblasts, and keratinocytes.
"It is increasingly important to design cell culture assays that closely mimic the behavior of cells in living tissues," said Carl Schrott, Director of Marketing for Regenerative Medicine and Research Cell Culture at Sigma-Aldrich. "Through this partnership, we will offer our customers new tools to grow stem cells that resemble their in vivo counterparts, and the high-quality antibodies needed to study them."
To access Sigma-Aldrich's extensive portfolio of reagents and kits for life science researchers, visit www.sigma-aldrich.com/lifescience
Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. Sigma-Aldrich has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 36 countries and has 8,000 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service.
About AlphaGenix, Inc.: AlphaGenix is a life science company that develops novel products and technologies for basic and clinical research with a particular emphasis on stem cell markers, biomaterials and regenerative medicine. The biomaterials product focus involves the design and application of 3-dimensional biomaterials comprised of extracellular matrix components and peptide nanofibers that have cell culture and tissue engineering applications. In addition, the company conducts regenerative medicine research that involves basic science and translational preclinical research using stem cell regulatory network discoveries and novel preclinical studies utilizing animal models with a focus on neurological disease. For more information on AlphaGenix and its products, which are sold worldwide, visit our website at www.alphagenix.com
Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Companies' expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Companies' operations and conditions in the markets the Companies serve. The Companies do not undertake any obligation to update these forward-looking statements.
For more information, please click here
St. Louis, MO, USA
Copyright © PR Newswire Association LLC.
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Creation of 'Rocker' protein opens way for new smart molecules in medicine, other fields December 18th, 2014
How does enzymatic pretreatment affect the nanostructure and reaction space of lignocellulosic biomass? December 18th, 2014
Silicon Valley-Based Foresight Valuation Launches STR-IPô, a New Initiative for Startups to Discover the Value of Their Intellectual Property December 18th, 2014
Iranian Scientists Use Nanotechnology to Increase Power, Energy of Supercapacitors December 18th, 2014
SUNY Poly NanoCollege Faculty Member Selected as American Physical Society Fellow: SUNY Poly Associate Professor of Nanoscience Dr. Vincent LaBella Recognized for Significant Technological Innovations that Enable Interactive Learning December 17th, 2014
New 'electronic skin' for prosthetics, robotics detects pressure from different directions December 10th, 2014
SEMATECH Reports Significant Progress in EUV Resist Outgas Testing: Technologists from SEMATECH and JSR demonstrate outgas test results that further enable EUV lithography for high-volume manufacturing readiness December 3rd, 2014
Toward a low-cost 'artificial leaf' that produces clean hydrogen fuel December 3rd, 2014